CTIS2022-502606-33-00进行中（未招募）1 期
A Phase III, Randomized, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) - D516AC00001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female, at least 18 years of age. For patients aged <20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative., Histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease (according to Version 8 of the IASLC Cancer Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016])., Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a Mulit-disciplinary Team (MDT) evaluation (which should include a thoracic surgeon, specialised in oncologic procedures)., Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at enrolment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing., A tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).
排除标准
- •Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD., Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 (at least 3 weeks prior), History of another primary malignancy (including any known or suspected synchronous primary lung cancer), except for the following: Malignancy treated with curative intent and with no known active disease =2 years before the first dose of investigational product (IP) and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease; Adequately treated carcinoma in situ without evidence of disease; Any synchronous Stage IA primary lung cancer that is =2 cm and planned to be resected during surgery for the Stage II to IIIB N2 lung tumour., Patients who have pre-operative radiotherapy treatment as part of their care plan, Mixed small cell and NSCLC histology, Stages I, IIIB N3, IIIC, IVA, and IVB NSCLC, T4 tumours infiltrating the great vessels, the carina, the trachea, the oesophagus, the heart, and/or the vertebral body; and/or any bulky N2 disease., Patients who are candidates to undergo only segmentectomies or wedge resections, Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug, Prior treatment with EGFR-TKI therapy
研究者
相似试验
进行中（未招募）
1 期
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome - SICCANOVEKeratoconjunctivitis sicca (KCS), or dry eye syndromeMedDRA version: 9.1 Level: PT Classification code 10023350 Term: Keratoconjunctivitis siccaEUCTR2007-000029-23-GBovagali Pharma S.A.482
进行中（未招募）
1 期
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome - SICCANOVEKeratoconjunctivitis sicca (KCS), or dry eye syndromeMedDRA version: 9.1Level: PTClassification code 10023350Term: Keratoconjunctivitis siccaEUCTR2007-000029-23-FRovagali Pharma S.A.482
进行中（未招募）
1 期
Short Treatment with Amoxicillin in Children with Acute Streptococcal PharyngitisAcute Streptococcal PharyngitisMedDRA version: 20.0Level: PTClassification code 10034839Term: Pharyngitis streptococcalSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-004143-24-ESHospital Universitario Niño Jesus710
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial ofNOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehiclein Patients with Moderate to Severe Dry Eye Syndrome - SICCANOVEKeratoconjunctivitis siccaEUCTR2007-000029-23-ITOVAGALI PHARMA S.A.482
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome - SICCANOVEEUCTR2007-000029-23-DEovagali Pharma S.A.482